Compile Data Set for Download or QSAR
Report error Found 138 Enz. Inhib. hit(s) with all data for entry = 11780
TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647342(4-(7-(1- cyclopropyl- 1H-pyrazol-4- yl)imidazo[1,2...)
Affinity DataIC50: 0.101nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647344(US20240025892, Example 51)
Affinity DataIC50: 0.412nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647338(US20240025892, Example 45)
Affinity DataIC50: 0.579nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647340(4-(7-(1-ethyl-1H- pyrazol-4- yl)imidazo[1,2- a]pyr...)
Affinity DataIC50: 0.855nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647298(2-(5-((3-methyloxetan- 3-yl)methoxy)-1H- benzo[d]i...)
Affinity DataIC50: 0.979nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647310(US20240025892, Example 17)
Affinity DataIC50: 1.04nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647345(US20240025892, Example 52)
Affinity DataIC50: 1.11nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
The General Hospital

US Patent
LigandPNGBDBM647308(US20240025892, Example 15)
Affinity DataIC50: 1.12nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
The General Hospital

US Patent
LigandPNGBDBM647344(US20240025892, Example 51)
Affinity DataIC50: 1.18nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
The General Hospital

US Patent
LigandPNGBDBM647342(4-(7-(1- cyclopropyl- 1H-pyrazol-4- yl)imidazo[1,2...)
Affinity DataIC50: 1.43nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647348(US20240025892, Example 55)
Affinity DataIC50: 1.48nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647353(2-cyclopropyl-5- (2,6-dimethoxy- 4-(7-(1-methyl- 1...)
Affinity DataIC50: 1.49nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
The General Hospital

US Patent
LigandPNGBDBM647345(US20240025892, Example 52)
Affinity DataIC50: 1.64nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
The General Hospital

US Patent
LigandPNGBDBM647353(2-cyclopropyl-5- (2,6-dimethoxy- 4-(7-(1-methyl- 1...)
Affinity DataIC50: 1.64nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647346(2-(4-(6-(1- cyclopropyl-1H- pyrazol-4- yl)pyrazolo...)
Affinity DataIC50: 1.77nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647308(US20240025892, Example 15)
Affinity DataIC50: 1.91nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647303(US20240025892, Example 10)
Affinity DataIC50: 2.11nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
The General Hospital

US Patent
LigandPNGBDBM647342(4-(7-(1- cyclopropyl- 1H-pyrazol-4- yl)imidazo[1,2...)
Affinity DataIC50: 2.16nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
The General Hospital

US Patent
LigandPNGBDBM647338(US20240025892, Example 45)
Affinity DataIC50: 2.21nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
The General Hospital

US Patent
LigandPNGBDBM647298(2-(5-((3-methyloxetan- 3-yl)methoxy)-1H- benzo[d]i...)
Affinity DataIC50: 2.24nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647347(4-(6-(1-cyclopropyl- 1H-pyrazol-4- yl)pyrazolo[1,5...)
Affinity DataIC50: 2.24nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647337(US20240025892, Example 44)
Affinity DataIC50: 2.34nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647343(4-(7-(1- (oxetan-3-yl)- 1H-pyrazol-4- yl)imidazo[1...)
Affinity DataIC50: 2.34nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
The General Hospital

US Patent
LigandPNGBDBM647346(2-(4-(6-(1- cyclopropyl-1H- pyrazol-4- yl)pyrazolo...)
Affinity DataIC50: 2.62nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
The General Hospital

US Patent
LigandPNGBDBM647348(US20240025892, Example 55)
Affinity DataIC50: 2.66nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647354(US20240025892, Example 61)
Affinity DataIC50: 3.07nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647309(US20240025892, Example 16)
Affinity DataIC50: 3.39nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647356(US20240025892, Example 63)
Affinity DataIC50: 3.40nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
The General Hospital

US Patent
LigandPNGBDBM647303(US20240025892, Example 10)
Affinity DataIC50: 3.71nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
The General Hospital

US Patent
LigandPNGBDBM647338(US20240025892, Example 45)
Affinity DataIC50: 3.83nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647334(US20240025892, Example 41)
Affinity DataIC50: 4.11nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
The General Hospital

US Patent
LigandPNGBDBM647340(4-(7-(1-ethyl-1H- pyrazol-4- yl)imidazo[1,2- a]pyr...)
Affinity DataIC50: 4.16nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647306(US20240025892, Example 13)
Affinity DataIC50: 4.19nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
The General Hospital

US Patent
LigandPNGBDBM647308(US20240025892, Example 15)
Affinity DataIC50: 4.37nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
The General Hospital

US Patent
LigandPNGBDBM647309(US20240025892, Example 16)
Affinity DataIC50: 4.44nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
The General Hospital

US Patent
LigandPNGBDBM647353(2-cyclopropyl-5- (2,6-dimethoxy- 4-(7-(1-methyl- 1...)
Affinity DataIC50: 4.45nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
The General Hospital

US Patent
LigandPNGBDBM647345(US20240025892, Example 52)
Affinity DataIC50: 4.77nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647305(US20240025892, Example 12)
Affinity DataIC50: 4.90nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647315(N-((1H- benzo[d]imidazol-2- yl)methyl)-3-(4- cyano...)
Affinity DataIC50: 5.58nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647299(2-(5-((3-methyloxetan- 3-yl)methoxy)-1H- benzo[d]i...)
Affinity DataIC50: 5.75nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647336(US20240025892, Example 43)
Affinity DataIC50: 5.89nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
The General Hospital

US Patent
LigandPNGBDBM647307(US20240025892, Example 14)
Affinity DataIC50: 6.08nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
The General Hospital

US Patent
LigandPNGBDBM647344(US20240025892, Example 51)
Affinity DataIC50: 6.49nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647328(US20240025892, Example 35)
Affinity DataIC50: 7.55nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647341(US20240025892, Example 48)
Affinity DataIC50: 7.65nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
The General Hospital

US Patent
LigandPNGBDBM647354(US20240025892, Example 61)
Affinity DataIC50: 8.25nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK1(Human)
The General Hospital

US Patent
LigandPNGBDBM647340(4-(7-(1-ethyl-1H- pyrazol-4- yl)imidazo[1,2- a]pyr...)
Affinity DataIC50: 8.34nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647300(1-(2-(5-((3- methyloxetan-3- yl)methoxy)-1H- benzo...)
Affinity DataIC50: 8.35nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK3(Human)
The General Hospital

US Patent
LigandPNGBDBM647361(US20240025892, Example 68)
Affinity DataIC50: 8.67nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase SIK2(Human)
The General Hospital

US Patent
LigandPNGBDBM647350(2-ethyl-5-(2- methoxy-4-(7- (1-methyl-1H- pyrazol-...)
Affinity DataIC50: 8.76nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 138 total ) | Next | Last >>
Jump to: